Noxafil (posaconazole)

Azacitidine was administered after dialysis sessions, while venetoclax dosing was adjusted because of concomitant posaconazole prophylaxis. Approximately one year after diagnosis, relapsed AML was identified on peripheral blood flow cytometry. This case highlights the feasibility of venetoclax-based lower-intensity therapy in selected dialysis-dependent AML patients while underscoring the persistent therapeutic limitations and adverse prognosis associated with relapsed disease in this population.

P2, N=82, Completed, Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting --> Completed | N=50 --> 82 | Trial completion date: Jul 2025 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026

Midostaurin clearance was delayed during co-administration. Midostaurin therapeutic drug monitoring may serve for decision-making when DDI with CYP3A4 inhibitors is suspected.

P3, N=664, Not yet recruiting, University of Minnesota | Initiation date: May 2026 --> Sep 2026

P1/2, N=84, Recruiting, AstraZeneca

In multivariable analysis, patients who received azole AFP did not have improved survival (HR 1.29, 95% CI 1.10-1.53, P = .004) compared to patients who did not (median OS 10 months vs. 11 months), with similar lack of benefit across agents: voriconazole (HR 1.04, p = 0.75), fluconazole (HR 1.26, p = 0.039), isavuconazole (1.52, p = 0.048), and posaconazole (HR 1.62, p = 0.005). Routine azole AFP does not improve overall survival in patients receiving Ven/HMA, contrasting with proven benefits in intensive chemotherapy, likely due to lower fungal infection risk combined with the complexities of managing drug-drug interactions in routine practice, as evidenced by high rates of inadequate venetoclax dose adjustment in this cohort.

The trough concentrations of venetoclax were 9326.88 ± 12,169.05 ng/mL in patients treated with venetoclax alone, and 31,623.55 ± 28,453.67 ng/mL in patients treated with venetoclax in combination with posaconazole. A rapid and simple method was established and successfully applied to the simultaneous determination of the concentrations of venetoclax and posaconazole in AML patients, providing a basis for TDM and clinical pharmacokinetic analysis of these drugs in AML patients.

P3, N=602, Completed, Mundipharma Research Limited | Active, not recruiting --> Completed

P3, N=602, Active, not recruiting, Mundipharma Research Limited | Completed --> Active, not recruiting

P2, N=72, Recruiting, Shandong Cancer Hospital and Institute | N=20 --> 72

Furthermore, flow cytometry and colony formation assays revealed that PCZ attenuates and reduces the apoptotic/necrotic effects of ATO. In conclusion, PCZ synergistically and effectively reduces the adverse cytotoxic effects of ATO in lung cancer cells, providing a promising new therapeutic strategy for lung cancer treatment.

P=N/A, N=360, Completed, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Completed